Drug Profile
INXN 4001
Alternative Names: INXN-4001; RCSI INXN-4001Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Xogenex
- Developer Triple-Gene
- Class Cardiovascular therapies; Gene therapies; Heart failure therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Heart-failure in USA (Parenteral, Infusion)
- 14 Aug 2020 Precigen completes enrolment in the phase I trial for Heart failure in USA (Parenteral) (NCT03409627)
- 12 Aug 2020 Triple-Gene and Precigen completes the phase I trial for Heart failure in USA (Parenteral) (NCT03409627)